Multiple system atrophy is associated with changes in peripheral insulin-like growth factor system

Movement Disorders

Volumn 25, Issue 15, 2010, Pages 2621-2626

  Pellecchia, Maria Teresa ^a   Pivonello, Rosario ^a   Longo, Katia ^a,b   Manfredi, Michela ^c   Tessitore, Alessandro ^d   Amboni, Marianna ^a,b   Pivonello, Claudia ^a   Rocco, Mariangela ^a   Cozzolino, Autilia ^a   Colao, Annamaria ^a   Barone, Paolo ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Institute Hermitage Capodimonte   (Italy)

^c Department of Neurorehabilitation   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Insulin; Insulin like growth factors; Multiple system atrophy

Indexed keywords

INSULIN; LEVODOPA; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOCRINE SYSTEM; FEMALE; HOEHN AND YAHR RATING SCALE; HUMAN; INSULIN BLOOD LEVEL; MALE; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; PROTEIN FUNCTION; SCORING SYSTEM; SHY DRAGER SYNDROME; UNIFIED MULTIPLE SYSTEM ATROPHY RATING SCALE;

AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; SEX FACTORS; SOMATOMEDINS; STATISTICS, NONPARAMETRIC;

EID: 78349289586     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23320     Document Type: Article

References (38)

1. Quinn N. Multiple system atrophy. In: Marsden CD, Fahn S, editors. Movement Disorders III. London: Butterworth; 1994. p 262-281.
2. Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004; 3: 93-103.
3. Ajo R, Cacicedo L, Navarro C, Sanchez-Franco F. Growth hormone action on proliferation and differentiation of cerebral cortical cells from fetal rat. Endocrinology 2003; 144: 1086-1097.
4. Aberg MA, Aberg ND, Hedbacker H, Oscarsson J, Eriksson Ps. Peripheral infusion of IGF-I selectively indices neurogenesis in the adult rat hippocampus. J Neurosci 2000; 20: 2896-2903.
5. Koopmans GC, Brans M, Gomez-Pinilla F, et al. Circulating insulin-like growth factor I and functional recovery from spinal cord injury under enriched housing conditions. Eur J Neurosci 2006; 23: 1035-1046.
6. Pu SF, Zhuang HX, Marsh DJ, Ishii DN. Insulin-like growth factor-II increase and IGF is required for postnatal rat spinal motoneuron survival following sciatic nerve axotomy. J Neurosci Res 1999; 55: 9-16.
7. Holmberg B, Johansson J, Poewe W, et al. Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. Mov Disord 2007; 8: 1138-1144.
8. Kimber JR, Watson L, Mathias CJ. Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. Lancet 1997; 349: 1877-1881.
9. Pellecchia MT, Longo K, Pivonello R, et al. Multiple system atrophy is distinguished from idiopathic Parkinson's disease by the arginine growth hormone stimulation test. Ann Neurol 2006; 60: 611-615.
10. Pellecchia MT, Pivonello R, Salvatore E, et al. Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late-onset cerebellar ataxia. Clin Endocrinol 2005; 62: 428-433.
11. Kimber J, Watson L, Mathias CJ. Neuroendocrine responses to levodopa in multiple system atrophy. Mov Disord 1999; 14: 981-987.
12. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670-676.
13. Torres-Aleman I, Barrios V, Lledo A, Berciano J. The insulin-like growth factor I system in cerebellar degeneration. Ann Neurol 1996; 39: 335-342.
14. Bondy CA. Transient IGF-I expression during the maturation of functionally related central projectons neurons. J Neurosci 1991; 11: 3442-3455.
15. Garcia-Segura LM, Perez J, Pons S, et al. Localization of insulin-like growth factor I (IGF-I)-like inmmunoreactivity in the rat brain. Brain Res 1991; 560: 167-174.
16. Werther GA, Abate M, Hogg A, et al. Localization of insulin-like growth factor-I mRNA in rat brain by in situ hybridization-relationship to IGF-I receptors. Mol Endocrinol 1990; 4: 773-778.
17. Torres-Aleman I, Pons S, Santo-Benito F. Survival of Purkinje cells in cerebellar culture is increased by insulin-like growth factor I. J Neurosci Res 1992; 4: 864-869.
18. Bondy CA, Werner H, Roberts CJ, Le Roith D. Cellular pattern of type-1 insulin-like growth factor receptor gene expression during maturation of the rat brain: comparison with insulin-like growth factors I and II. Neuroscience 1992; 46: 909-923.
19. De Keyser J, Wilczak N, De Backer J, Herroelen L, Vauquelin G. Insulin-like growth factor-I receptors in human brain and pituitary gland: an autoradiographic study. Synapse 1994; 17: 196-202.
20. Vig PJ, Desaiah D, Joshi P, Subramony SH, Fratkin JD, Currier RD. Decreased insulin-like growth factor I-mediated protein tyrosine phosphorylation in human olivopontocerebellar atrophy and lurcher mutant mouse. J Neurol Sci 1994; 124: 38-44.
21. Bilic E, Bilic E, Rudan I, et al. Comparison of the growth hormone, IGF-I and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls. Eur J Neurol 2006; 13: 1340-1345.
22. Busiguina S, Fernandez A, Barrios V, et al. Neurodegeneration is associated to changes in serum insulin-like growth factors. Neurobiol Dis 2000; 7: 657-665.
23. Vardy ER, Rice PJ, Bowie PC, Holmes JD, Grant PJ, Hooper NM. Increased circulating insulin-like growth factor-I in late-onset Alzheimer's disease. J Alzheimers Dis 2007; 12: 285-290.
24. Tham A, Nordberg A, Grissom FE, et al. Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J Neural Transm 1993; 5: 165-176.
25. Mustafa A, Lannfelt L, Lilius L, Islam A, Winblad B, Adem A. Decreased plasma insulin-like growth factor-I level in familial Alzhimer's disease patients carrying the Swedish APP670/671 mutation. Dement Geriatr Cogn Disord 1999; 10: 446-451.
26. Moloney AA, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C. Defects in IGF-I receptor, insulin resistance and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-I and insulin signaling. Neurobiol Aging 2010; 31: 224-243.
27. Rosati G, Maioli M, Aiello I, Farris A, Agnetti V. Effects of long-term L-dopa therapy on carbohydrate metabolism in patients with Parkinson's disease. Eur Neurol 1976; 14: 229-239.
28. Godau J, Herfurth M, Kattner B, Gasser T, Berg D. Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 2010; 81: 536-538.
29. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrinol Rev 1995; 16: 3-34.
30. Frost RA, Lang CH. Growth factors in critical illness: regulation and therapeutic aspects. Curr Opin Clin Nutr Metab Care 1998; 1: 195-204.
31. Russo VC, Gluckman PD, Feldman EL, Werther GA. The insulin-like growth factor system and its pleiotropic functions in brain. Endocrinol Rev 2005; 26: 916-943.
32. Hawkes C, Kar S. The insulin-like growth factor-II/mannose-6-phosphate receptor: structure, distribution and function in the central nervous system. Brain Res Brain Res Rev 2004; 44: 117-140.
33. Stefanova N, Bucke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol 2009; 8: 1172-1178.
34. Wenning GK, Stefanova N. Recent development in multiple system atrophy. J Neurol 2009; 256: 1791-1808.
35. Folli F, Bonfanti L, Renard E, Kahn CR, Merighi A. Insulin receptor substrate-1 (IRS-1) distribution in the rat central nervous system. J Neurosci 1994; 14: 6412-6422.
36. Kao SY. Rescue of alpha-synuclin cytotoxicity by insulin-like growth factors. Biochem Biophys Res Commun 2009; 385: 434-438.
37. Reinhardt RR, Bondy CA. Insulin-like growth-factors cross the blood-brain barrier. Endocrinology 1994; 1753-1761.
38. Pulford BE, Ishii DN. Uptake of circulating insulin-like growth factors (IGFs) into cerebrospinal fluid appears to be independent of the IGF receptors as well as IGF-binding proteins. Endocrinology 2001; 142: 213-220.